Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association. Circulation 2016; 133(4): e38-e360.
Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the US: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief 2013; 133: 1-8.
Yoon SS, Gu Q, Nwankwo T, Wright JD, Hong Y, Burt V. Trends in blood pressure among adults with hypertension: the United States, 2003 to 2012. Hypertension 2015; 65(1): 54-61.
Giles TD, Materson BJ, Cohn JN, Kostis JB. Definition and classification of hypertension: An update. J Clin Hypertens (Greenwich) 2009; 11(11): 611-4.
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 2014; 23(1): 3-16.
Beevers G, Lip GYH, O’Brien E. ABC of hypertension - The pathophysiology of hypertension. BMJ 2001; 322(7291): 912-6.
McCormack T, Krause T, O’Flynn N. Management of hypertension in adults in primary care: A NICE guideline. Br J Gen Pract 2012; 62(596): 163-4.
James PA, Oparil S, Carter BL. 2014 evidence-based guideline for the management of high blood pressure in adults: A report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5): 507-20.
Foëx P, Sear JW. Hypertension: Pathophysiology and treatment. Contin Educ Anaesth Crit Care Pain 2004; 4(3): 71-5.
Delacroix S, Chokka RC, Worthley SG. Hypertension: Pathophysiology and treatment. J Neurol Neurophysiol 2014; 5: 250.
Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hypertension. Circ Res 2015; 116(6): 937-59.
Morris BJ. Renin, genes, microRNAs, and renal mechanisms involved in hypertension. Hypertension 2015; 65(5): 956-62.
Honour JW. Historical perspective: Gut dysbiosis and hypertension. Physiol Genomics 2015; 47(10): 443-6.
Jose PA, Raj D. Gut microbiota in hypertension. Curr Opin Nephrol Hypertens 2015; 24(5): 403-9.
Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464(7285): 59-65.
Brestoff JR, Artis D. Commensal bacteria at the interface of host metabolism and the immune system. Nat Immunol 2013; 14: 676-84.
Macfarlane S, Macfarlane GT. Regulation of short-chain fatty acid production. Proc Nutr Soc 2003; 62: 67-72.
Hoverstad T, Midtvedt T. Short-chain fatty acids in germfree mice and rats. J Nutr 1986; 116: 1772-6.
Pevsner-Fischer M, Blacher E, Tatirovsky E, Ben-Dov IZ, Elinav E. The gut microbiome and hypertension. Curr Opin Nephrol Hypertens 2017; 26(1): 1-8.
Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009; 461: 1282-6.
Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005; 122: 107-18.
Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9: 313-23.
Segain JP, Raingeard de la Bletiere D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn’s disease. Gut 2000; 47: 397-403.
Mortensen FV, Nielsen H, Mulvany MJ, Hessov I. Short chain fatty acids dilate isolated human colonic resistance arteries. Gut 1990; 31: 1391-4.
Nutting CW, Islam S, Daugirdas JT. Vasorelaxant effects of short chain fatty acid salts in rat caudal artery. Am J Physiol 1991; 261(2 Pt 2): H561-7.
Pluznick JL. Renal and cardiovascular sensory receptors and blood pressure regulation. Am J Physiol Renal Physiol 2013; 305: F439-44.
Pluznick JL, Zou DJ, Zhang X, et al. Functional expression of the olfactory signaling system in the kidney. Proc Natl Acad Sci USA 2009; 106: 2059-64.
Pluznick JL, Protzko RJ, Gevorgyan H, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA 2013; 110: 4410-5.
Le Poul E, Loison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003; 278: 25481-9.
Keshaviah PR. The role of acetate in the etiology of symptomatic hypotension. Artif Organs 1982; 6: 378-87.
Brown AJ, Goldsworthy SM, Barnes AA, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003; 278: 11312-9.
Mell B, Jala VR, Mathew AV, et al. Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol Genomics 2015; 47: 187-97.
Dahl LK, Heine M. Primary role of renal homografts in setting chronic blood pressure levels in rats. Circ Res 1975; 36: 692-6.
Elijovich F, Weinberger MH, Anderson CA. Salt sensitivity of blood pressure: a scientific statement from the American Heart Association. Hypertension 2016; 68: e7-e46.
Kristev A, Mitkov D, Lukanov J. Influence of short-chain fatty acids on vascular tone. Int J Exp Pathol 1991; 72: 475-80.
Yang T, Santisteban MM, Rodriguez V, et al. Gut dysbiosis is linked to hypertension. Hypertension 2015; 65: 1331-40.
Aoki K, Yamori Y, Ooshima A, Okamoto K. Effects of high or low sodium intake in spontaneously hypertensive rats. Jpn Circ J 1972; 36: 539-45.
Durgan DJ, Bryan RM Jr. Cerebrovascular consequences of obstructive sleep apnea. J Am Heart Assoc 2012; 1: e000091.
Quan SF, Howard BV, Iber C, et al. The sleep heart health study: Design, rationale, and methods. Sleep 1997; 20: 1077-85.
Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283: 1829-36.
Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ 2000; 320: 479-82.
Durgan DJ, Ganesh BP, Cope JL, et al. Role of the gut microbiome in obstructive sleep apnea-induced hypertension. Hypertension 2016; 67: 469-74.
Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368: 1575-84.
Bomfim GF, Dos Santos RA, Oliveira MA, et al. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci (Lond) 2012; 122: 535-43.
Bomfim GF, Echem C, Martins CB, et al. Toll-like receptor 4 inhibition reduces vascular inflammation in spontaneously hypertensive rats. Life Sci 2015; 122: 1-7.
McCarthy CG, Wenceslau CF, Goulopoulou S, et al. Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. Cardiovasc Res 2015; 107: 119-30.
Desvarieux M, Demmer RT, Jacobs DR, et al. Periodontal bacteria and hypertension: the oral infections and vascular disease epidemiology study (INVEST). J Hypertens 2010; 28: 1413-21.
Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002; 288: 1882-8.
Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117-24.
Nakamura Y, Masuda O, Takano T. Decrease of tissue angiotensin I-converting enzyme activity upon feeding sour milk in spontaneously hypertensive rats. Biosci Biotechnol Biochem 1996; 60: 488-9.
Fuglsang A, Rattray FP, Nilsson D, Nyborg NC. Lactic acid bacteria: inhibition of angiotensin converting enzyme in vitro and in vivo. Antonie van Leeuwenhoek 2003; 83: 27-34.
Liu CF, Tung YT, Wu CL, et al. Antihypertensive effects of Lactobacillus fermented milk orally administered to spontaneously hypertensive rats. J Agric Food Chem 2011; 59: 4537-43.
Beltran-Barrientos LM, Hernandez-Mendoza A, Torres-Llanez MJ, et al. Invited review: fermented milk as antihypertensive functional food. J Dairy Sci 2016; 99: 4099-110.
Nakamura Y, Yamamoto N, Sakai K, et al. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci 1995; 78: 777-83.
Masuda O, Nakamura Y, Takano T. Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. J Nutr 1996; 126: 3063-8.
Hata Y, Yamamoto M, Ohni M, et al. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr 1996; 64: 767-71.
Aihara K, Kajimoto O, Hirata H, et al. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J Am Coll Nutr 2005; 24: 257-65.
Upadrasta A, Madempudi RS. Probiotics and blood pressure: Current insights. Integr Blood Press Control 2016; 9: 33-42.
Robles-Vera I, Toral M, Romero M, et al. Antihypertensive effects of probiotics. Curr Hypertens Rep 2017; 19(4): 26.
AbuMweis SS, Jew S, Ames NP. B-Glucan from barley and its lipid-lowering capacity: A meta-analysis of randomized, controlled trials. Eur J Clin Nutr 2010; 64: 1472-80.
Maki KC, Beiseigel JM, Jonnalagadda SS, et al. Whole-grain ready-to-eat oat cereal, as part of a dietary program for weight loss, reduces low-density lipoprotein cholesterol in adults with overweight and obesity more than a dietary program including low-fiber control foods. J Am Diet Assoc 2010; 110: 205-14.
Braaten JT, Wood PJ, Scott FW, et al. Oat gum lowers glucose and insulin after an oral glucose load. Am J Clin Nutr 1991; 53: 1425-30.
Wang Y, Ames NP, Tun HM, et al. High molecular weight barley beta-glucan alters gut microbiota toward reduced cardiovascular disease risk. Front Microbiol 2016; 7: 129.
Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-31.
Kemppainen KM, Ardissone AN, Davis-Richardson AG, et al. Early childhood gut microbiomes show strong geographic differences among subjects at high risk for type 1 diabetes. Diabetes Care 2015; 38: 329-32.
Ahn J, Sinha R, Pei Z, Dominianni C, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 2013; 105: 1907-11.
Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn’s disease: A randomized controlled trial. Gastroenterology 2002; 123: 33-40.
Wallace BD, Wang H, Lane KT, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010; 330: 831-5.
Haiser HJ, Gootenberg DB, Chatman K, et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 2013; 341: 295-8.
Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015; 528: 262-6.
Kaddurah-Daouk R, Baillie RA, Zhu H, et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One 2011; 6: e25482.